&lt;p&gt;Cost-Effectiveness Analysis of Spending on Research and Development to Address the Needs for Innovative Therapeutic Products in Indonesia&lt;/p&gt;

Suwantika, Auliya A.; Kautsar, Angga Prawira; Zakiyah, Neily; Abdulah, Rizky; Boersma, Cornelis; Postma, Maarten J.

doi:10.2147/tcrm.s260377

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Indonesia's health expenditure per capita is very low, which is only 3.1% of the total GDP. Indonesia's health expenditure per capita value is still below other ASEAN countries, such as Malaysia Original Research (USD 361), Vietnam (USD 36), Singapore (USD 1,804), and Thailand (USD 111) (Suwantika et al, 2020). Health expenditure is still considered a luxury item, so people tend to be low in spending their income on health needs (Shaikh and Gandjour, 2019).…”

Section: Challenges In Developing Pharmaceutical Raw Materials Indust...mentioning

confidence: 99%

Challenges and Policy Supports in Indonesian Pharmaceutical Raw Materials Industry

Hermawan,

Hadiyati,

Adiarso

et al. 2023

JAKI

View full text Add to dashboard Cite

Background: Indonesian pharmaceutical industry is experiencing many challenges, spesficically their raw materials mostly are imported products. Several factors that cause the pharmaceutical raw materials industry to be challenging are lack of mastery of technology, lack of government support, low budget for R&D, high costs of development and time consuming, and low innovation incentives. Aims: This study aims to conduct a study on the strategies for developing the pharmaceutical raw material industry in Indonesia Methods: This study employed a qualitative method, the data triangulation gathered from interviews and discussions with several industries and institutions. The study was conducted for six months in 2022. Results: The policies that are required to be implemented to make the pharmaceutical raw materials industry thrive are (i) the presence of a clear grand strategy, (ii) determining the priority of pharmaceutical raw materials based on industrial needs, (iii) protecting domestic products, (iv) increasing health spending, (v) strengthening basic chemical product, and (vi) increasing the budget for R&D. Conclusion: Some policies that can be enhanced include providing incentives and policies that favor the local pharmaceutical raw material industry, ranging from regulated prices, putting an end to dependence on imported products, tax incentives, domestic products protection through import tariff policies, energy subsidies, technology transfers, et cetera. Keywords: pharmaceutical raw materials, policy, pharmaceutical

show abstract

Section: Challenges In Developing Pharmaceutical Raw Materials Indust...mentioning

confidence: 99%

Challenges and Policy Supports in Indonesian Pharmaceutical Raw Materials Industry

Hermawan,

Hadiyati,

Adiarso

et al. 2023

JAKI

View full text Add to dashboard Cite

show abstract

“…However, a growing body of literature regarding the discussions on science, technology and innovation in Indonesia have been limited (Zuhal, 2008). Similarly, other research areas has been conducted, including: R&D performance on the budget (Arifin, 2011;Mulyanto, 2014); researcher performance (Lukman et al, 2018); R&D performance on exports (Yang & Chen, 2012); R&D spending efficiency (Afzal & Lawrey, 2014;Suwantika et al, 2020); scientific productivity and collaboration of universities with government R&D institutions (Setyono & Aeni, 2018); as well as cooperation and collaboration of R&D institutions (Lestari et al, 2019;Surminah, 2013;Widjajanti et al, 2020). Similarly, other studies were conducted to reveal the interactions in the triple helix model (Fitriana, 2017;Lukmanul Hakim et al, 2018;Muljaningsih et al, 2018;Muzakir, 2019;Nurzal & Waluyo, 2012;Pennink, 2012;Perwitasari & Sutrisnanto, 2015;, Quadruple Helix (Moradi & Dokhani, 2020;Pitaloka & Humaedi, 2020;Widjajani et al, 2016Widjajani et al, , 2018, Penta Helix (Deliana et al, 2017;Effendi et al, 2016;Hardianto et al, 2019;Muhyi & Chan, 2017;Rinaldi et al, 2020;Sihotang et al, 2019;Sudiana et al, 2020aSudiana et al, , 2020bWidowati et al, 2019), National Innovation System (Baark, 2016;Triyono & Prihadyanti, 2017), Regional Innovation System (Amriani & Prihatin, 2019;Ismiatun, 2015;Lestari et al, 2019;…”

mentioning

confidence: 99%

The policy dynamics of Indonesia's science, technology, and innovation system (STI system): Current state of research and literature construction

Putera

2022

JOSTIP

View full text Add to dashboard Cite

Policy dynamics is not merely a discussion encapsulating the policy cycle. Further, policy dynamics is widely applied to examine the evolution of policy, political dynamics, policy change, and policy development. In addition, policy dynamics have been implemented in a number of different topics and research areas. Discourses include changes in science, technology, and innovation (STI) policies in Indonesia in the last three years, gaining insight to be studied under policy dynamics. However an initial study with a bibliometric approach is required prior to conducting a review. This initial study aims to determine the current state of research and literature construction. This study employs bibliometric analysis by using VOSViewer. The results of this study include the mapping for several research on science, technology and innovation systems in Indonesia, in which the topics have been dominated by triple helix during 2010-2020, particularly in science Techno Park and innovation. In addition, approximately 55.7% of STI System in Indonesia topics are widely published in national publications such as national journals, and 44.3% are published internationally.

show abstract

Economic perspectives in pharmaceuticals: market dynamics and pricing of medications

Borysiuk,

Shevchenko,

Tiutiunnyk

et al. 2024

Rev. Clin. Pharmacol. Pharmacokinet., Int. Ed.

View full text Add to dashboard Cite

Background: Analysing the modern pharmaceutical market is crucial for making management decisions, forming strategies, and ensuring competitiveness in this sector. Aim: Determination of the impact of various economic factors of the pharmaceutical industry on market conditions and development of economically justified areas of cost formation in the pharmaceutical market. Materials and Methods: A systematic review of scientific publications in the search databases Scopus, Web of Science, Medline, and Google Scholar was conducted. Statistical research methods used are observation, index and regression analysis. The methods of benchmarking analysis and interpretation were applied. Results: A detailed examination of published works by scientists and doctors has highlighted critical problems in forming the cost of medicinal products in the pharmaceutical market. The use of medicines worldwide and in individual countries has been considered, and a trend of increasing revenue in the global pharmaceutical market has been identified. The main approaches to forming pricing models in the pharmaceutical industry have been summarised. The peculiarities of the formation of EU legislation on the registration, production, sale, and quality control of medicinal products have been highlighted. The characteristics of the functioning of reimbursement programmes in certain countries worldwide have been described. A benchmarking analysis of the pharmaceutical market economy in Ukraine and the European Union has been conducted. Conclusions: The main directions for improving pricing policy in the modern pharmaceutical market have been outlined. It has been established that the main directions for forming the cost of medicinal products are expenses on research and development, costs of goods sold and patent expenses, marketing and advertising, regulatory and permitting procedures, and market competition.

show abstract

<p>Cost-Effectiveness Analysis of Spending on Research and Development to Address the Needs for Innovative Therapeutic Products in Indonesia</p>

Abstract: Background: The annual gross domestic expenditure on research and development (GERD) per capita of Indonesia ($24) remains relatively lower than the annual GERD per capita of neighboring countries, such as Vietnam

Cited by 3 publications

References 32 publications

Challenges and Policy Supports in Indonesian Pharmaceutical Raw Materials Industry

Challenges and Policy Supports in Indonesian Pharmaceutical Raw Materials Industry

The policy dynamics of Indonesia's science, technology, and innovation system (STI system): Current state of research and literature construction

Economic perspectives in pharmaceuticals: market dynamics and pricing of medications

Contact Info

Product

Resources

About